FLUANXOL DEPOT 2% -LIQ IM 20MG/ML SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

FLUPENTIXOL DECANOATE

제공처:

LUNDBECK CANADA INC

ATC 코드:

N05AF01

INN (국제 이름):

FLUPENTIXOL

복용량:

20MG

약제 형태:

SOLUTION

구성:

FLUPENTIXOL DECANOATE 20MG

관리 경로:

INTRAMUSCULAR

패키지 단위:

10X1ML/2ML/10ML

처방전 유형:

Prescription

치료 영역:

THIOXANTHENES

제품 요약:

Active ingredient group (AIG) number: 0114584001; AHFS:

승인 상태:

MARKETED

승인 날짜:

1995-12-31

제품 특성 요약

_ _
_ _
_Page 1 of 35 _
November 17, 2017
PRODUCT MONOGRAPH
Pr
FLUANXOL
®
Flupentixol Tablets
(as flupentixol dihydrochloride)
0.5 mg, 3 mg, and 5 mg
Pr
FLUANXOL
®
DEPOT
Flupentixol Decanoate Intramuscular Injection
2% and 10% flupentixol decanoate
ANTIPSYCHOTIC AGENT
Lundbeck Canada Inc.
2600 Alfred-Nobel
Suite 400
St-Laurent, QC
H4S 0A9
Date of Revision:
December 12, 2017
Submission Control No : 209135
_ _
_ _
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................22
PART II: SCIENTIFIC INFORMATION
...............................................................................23
PHARMACEUTICAL INFORMATION
..........................................................................23
DETAILED PHARMACOLOGY
.................................................